【BIOSIS 7193 交流专区】 生物科学

APULA

APULA 发表于 22-4-2012 11:10 PM
再接再力，再创高峰。。。BIOSIS

好戏在后头

Kimz-kimz

APULA 发表于 8-8-2012 11:27 PM
好戏在后头

期望他创新高，然后上去2快，哈哈

APULA

再战江湖。。。Hari Raya!!!!!!

悠然阿修罗

icy97 发表于 1-8-2012 11:59 AM
證實大股東售股‧保優生對股價波動不知情

大馬  2012-08-01 11:15

谢谢分享

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2012	30/06/2011	30/06/2012	30/06/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,936	8,764	4,936	0
2	Profit/(loss) before tax	-1,626	-1,257	-1,626	0
3	Profit/(loss) for the period	-1,628	-1,425	-1,628	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,437	-1,182	-1,437	0
5	Basic earnings/(loss) per share (Subunit)	-1.37	-1.14	-1.37	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2800		0.2900

APULA

alanlam84 发表于 7-8-2012 06:59 AM
大佬，你要放的时候通知一声

BIOSIS GROUP BERHAD

Type	Announcement
Subject	OTHERS
Description	Change of Name of Subsidiary Company
Biosis Group Berhad wishes to announce that its wholly-owned subsidiary company, Biosis Nutraceuticals Sdn. Bhd. has changed its name to Biosis Development Sdn. Bhd. on 1 November 2012.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2012	30/09/2011	30/09/2012	30/09/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,546	4,163	9,482	0
2	Profit/(loss) before tax	-1,560	-1,595	-3,186	0
3	Profit/(loss) for the period	-1,563	-1,553	-3,191	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,247	-1,231	-2,684	0
5	Basic earnings/(loss) per share (Subunit)	-1.19	-1.17	-2.55	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2600		0.2900

APULA

保優生削資40仙‧3配5附加股籌資重組

大馬  2012-12-20 11:51
（吉隆坡19日訊）保優生（BIOSIS，7193，主板消費品組）建議削減股票面值40仙、3配5比例配售附加股等計劃，以籌資償還債務及充當營運資本用途。

取消私下配售
該公司在文告中指出，隨著推行上述新計劃，將放棄今年3月9日宣佈的私下配售1千零50萬股新股計劃。

該公司建議將面值50仙股票削減至10仙。目前該公司發行及繳足資本5千250萬令吉，由1億零500萬股每股面值50仙的股票組成。一旦將股票面值削減至10仙，將使該公司取得4千200萬令吉的資金。

過後，該公司將以“3配5＂比例配售附加股計劃，最高達2億4千166萬6千666股新股，或是最低1億7千500萬股新股，預料每股售價為10仙，使它最少可籌得1千750萬令吉的資金。

以股抵債
在債務資本化計劃中，該公司將發行1億4千萬股新股給債主，以當償還1千400萬令吉的債務。同時，該公司也發行1億8千萬股的特別土著股，或占擴大資本後的30.0%股權。

上述計劃預料在2013年首季完成。（星洲日報／財經）

BIOSIS GROUP BERHAD

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	BIOSIS GROUP BERHAD (“BIOSIS” OR “COMPANY”) (I)        PROPOSED PAR VALUE REDUCTION; (II)        PROPOSED RIGHTS ISSUE; (III)        PROPOSED DEBT CAPITALISATION; (IV)        PROPOSED BUMIPUTERA SPECIAL ISSUE; AND (V)        PROPOSED AMENDMENT (COLLECTIVELY REFERRED TO AS “PROPOSALS”)
On behalf of the Board of Directors of the Company, M&A Securities Sdn Bhd is pleased to announce that the Company is proposing to undertake the following: (a) Proposed reduction of its existing issued and paid-up share capital comprising ordinary shares of RM0.50 each in Biosis credited as fully paid-up via the cancellation of RM0.40 from the par value of each existing ordinary RM0.50 each in Biosis pursuant to Section 64 the Companies Act, 1965 (“Proposed Par Value Reduction”); (b) Proposed renounceable rights issue of up to 241,666,666 new ordinary shares of RM0.10 each in Biosis (“Rights Shares”) after the Proposed Par Value Reduction on the basis of five (5) Rights Shares for every three (3) ordinary shares of RM0.10 each in Biosis (“Biosis Shares”) held on an entitlement date to be determined later (“Proposed Rights Issue”); (c) Proposed capitalisation of debt owing by Biosis and its subsidiaries amounting to RM14,000,000 via the issuance of 140,000,000 new Biosis Shares to certain creditors (“Proposed Debt Capitalisation”); (d) Proposed special issue of up to 180,000,000 new Biosis Shares, representing up to 30.0% of the enlarged issued and paid up share capital (after the implementation of Proposed Rights Issue and Proposed Debt Capitalisation, referred to in (b) and (c) above but before the exercise of any outstanding warrants of the Company and based on the Minimum Scenario as defined in Section 2.2 of the attachment enclosed herein) to independent third party Bumiputera investor(s) to be identified; and (e) Proposed amendment to relevant clauses of the Memorandum and/or Articles of Association of the Company for the Proposed Par Value Reduction. This announcement is dated 19 December 2012.

Attachments Biosis - Announcement 19 December 2012.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2012	31/12/2011	31/12/2012	31/12/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,951	8,093	13,433	0
2	Profit/(loss) before tax	-713	-4,304	-3,899	0
3	Profit/(loss) for the period	-715	-4,366	-3,906	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	-511	-4,112	-3,195	0
5	Basic earnings/(loss) per share (Subunit)	-0.48	-4.00	-3.04	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2600		0.2900

icy97

BIOSIS GROUP BERHAD

Type	Announcement
Subject	PRACTICE NOTE 1 / GUIDANCE NOTE 5 NEW DEFAULT
Description	BIOSIS GROUP BERHAD (“BIOSIS” OR “COMPANY”) DEFAULT IN PAYMENT PURSUANT TO PRACTICE NOTE 1 (“PN1”) OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”) (“MMLR”)
1. INTRODUCTION The Board of Directors of BIOSIS (“Board”) wishes to announce that a subsidiary, Biosis Cosmeceuticals Sdn Bhd (“BCSB”) had on 18 March 2013 received a Writ of Summons and Statement of Claim from the advocates and solicitors acting on behalf of HSBC Bank Malaysia Berhad (“HSBC”) that BCSB has defaulted in repayment of principal sums and interest in respect of certain banking facilities pursuant to PN1 of the MMLR. The details of the said credit facilities and the relevant affected financial institutions are as follows:- Lender Type of facilities Company Amount outstanding Principal (RM) Interest (RM) HSBC Bank Malaysia Berhad Term Loan Biosis Cosmeceuticals Sdn Bhd 860,432.20 4,997.34 2. DETAILS OF DEFAULT In compliance with the MMLR, the details of the Default are as follows:- (a) Date of Default The date of default is 29 January 2013. (b) Reasons for the Default The reason for the Default was that the current cash flow generated from the operations of BIOSIS and its subsidiaries (“BIOSIS Group”) is insufficient to repay the outstanding amount. (c) Measures by the Company to address the Default BIOSIS is currently negotiating with HSBC towards a mutually agreeable settlement by way of disposal of assets and/or a fund raising exercise as announced on 19 December 2012. (d) Legal implications of the Default including the extent of the Company’s liability in respect of the obligations incurred under the agreements for the indebtedness The default may have a consequential impact on other on-going bank borrowings of BIOSIS Group. (e) Business, financial and operational impact of the Default on the Company At this point in time, the Default has no material impact on the operations of other operating subsidiaries of BIOSIS which are independent of BCSB. (f) Cross Default The Default with the above financial institution may trigger a cross default with other financial institutions of the BIOSIS Group. (g) Confirmation on subsidiary BCSB is a major subsidiary of BIOSIS. (h) Solvency declaration The Board shall provide a solvency declaration to Bursa Malaysia within three (3) market days from the date of this announcement. BIOSIS shall update on a monthly basis the status of the Default and the steps taken to address the Default until such time when the Default is remedied. This announcement is dated 20 March 2013.

icy97

BIOSIS GROUP BERHAD

Type	Announcement
Subject	OTHERS
Description	BIOSIS GROUP BERHAD ("BIOSIS" OR "COMPANY") DISPOSAL OF ENTIRE EQUITY INTEREST IN D'HAIR SHOP (M) SDN BHD, A WHOLLY-OWNED SUBSDIARY (ANNOUNCEMENT PURSUANT TO PARAGRAPH 9.19(24) OF MAIN MARKET LISTING REQUIREMENTS)
The Board of Directors of the Company wishes to announce that the Company had on 29 March 2013 entered into an agreement with Regular Accomplishment Sdn Bhd in relation to the Proposed Disposal. This announcement is dated 29 March 2013

Attachments Announcemt Sale of DHS.pdf

icy97

BIOSIS GROUP BERHAD

Type	Announcement
Subject	OTHERS
Description	BIOSIS GROUP BERHAD ("BIOSIS" OR "COMPANY") DISPOSAL OF ENTIRE EQUITY INTEREST IN D'HAIR SHOP (M) SDN BHD, A WHOLLY-OWNED SUBSDIARY (ANNOUNCEMENT PURSUANT TO PARAGRAPH 9.19(24) OF MAIN MARKET LISTING REQUIREMENTS)
Further to our general announcement on 29 March 2013 we are pleased to furnish herewith the following additional information: 1. The Proposed Disposal will give rise to a profit of RM1.00 at company level and a profit of RM1.122 million at Biosis Group level derived as follows: Details RM (‘000) Reversal of accumulated losses of DHSB 2,602 less: Provision for impairment loss on receivables (1,480) Profit from proposed disposal 1,122 This announcement is dated 1 April 2013.

icy97

BIOSIS GROUP BERHAD

Type	Announcement
Subject	PRACTICE NOTE 1 / GUIDANCE NOTE 5 NEW DEFAULT
Description	BIOSIS GROUP BERHAD (“BIOSIS” OR “COMPANY”) DEFAULT IN PAYMENT PURSUANT TO PRACTICE NOTE 1 (“PN1”) OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”) (“MMLR”)
1. INTRODUCTION The Board of Directors of BIOSIS (“Board”) wishes to announce that a subsidiary, Biosis Pharmaceuticals Sdn Bhd (“BPSB”) had on 24 April 2013 received a Letter of Cancellation and Recall of Overdraft Facilities from the advocates and solicitors acting on behalf of Malayan Banking Berhad (“MBB”) that BPSB has defaulted in repayment of principal sums and interest in respect of certain banking facilities pursuant to PN1 of the MMLR. The details of the said credit facilities and the relevant affected financial institutions are as follows:- Amount outstanding Lender Type of facilities Company Principal and Interest (RM) Malayan Banking Berhad Overdraft Biosis Pharmaceuticals Sdn Bhd 1,942,743.53 2. DETAILS OF DEFAULT In compliance with the MMLR, the details of the Default are as follows:- (a) Date of Default The date of default is 29 February 2013. (b) Reasons for the Default The reason for the Default was that the current cash flow generated from the operations of BIOSIS and its subsidiaries (“BIOSIS Group”) is insufficient to repay the outstanding amount. (c) Measures by the Company to address the Default BIOSIS had on 9 April 2013 obtained a Restraining Order pursuant to Section 176(1) and Section 176(10) of the Companies Act, 1965 to restrain any and all proceedings and/or actions and/or further proceedings in any suits and/or proceedings and/or actions against the Company and Biosis Cosmeceuticals Sdn Bhd (“BCSB”), Biosis Marketing Sdn Bhd ("BMSB”), both wholly-owned subsidiaries of the Company and Biosis Pharmaceuticals Sdn Bhd (“BPSB”) a 83% owned subsidiary of the Company, and/or in respect of BIOSIS, BCSB, BMSB and BPSB and/or their assets and/or assets employed in their businesses, including but not limited to any winding-up, execution, arbitration proceedings, act of repossession or purported repossession, the appointment of receivers and managers, liquidators, provisional liquidators or otherwise whatsoever, by any creditors and/or purported creditors or any other persons whatsoever, except by leave of the Court, for a period of six (6) months from 9 April 2013 (“Restraining Order”). BIOSIS is in the midst of formalizing proposals for schemes of arrangement for the creditors and/or a fund raising exercise as announced on 19 December 2012. (d) Legal implications of the Default including the extent of the Company’s liability in respect of the obligations incurred under the agreements for the indebtedness The default may have a consequential impact on other on-going bank borrowings of BIOSIS Group. (e) Business, financial and operational impact of the Default on the Company At this point in time, the Default has no material impact on the operations of other operating subsidiaries of BIOSIS which are independent of BPSB. (f) Cross Default The Default with the above financial institution may trigger a cross default with other financial institutions of the BIOSIS Group. (g) Confirmation on subsidiary BPSB is a major subsidiary of BIOSIS. (h) Solvency declaration The Board has provided a solvency declaration to Bursa Malaysia on 25 March 2013. BIOSIS shall update on a monthly basis the status of the Default and the steps taken to address the Default until such time when the Default is remedied. This announcement is dated 24 April 2013.

APULA

拜一见。。。。。。Biosis

david_88

会上涨？？？

APULA

williamnkk81 发表于 31-3-2012 12:20 AM
回复 25# APULA

如何看这股？下半场。。。。

williamnkk81

APULA 发表于 13-5-2013 12:25 PM
如何看这股？下半场。。。。

哈哈。。。。

chinesesp

williamnkk81 发表于 13-5-2013 04:32 AM
哈哈。。。。

haha??未卜先知？？

williamnkk81

chinesesp 发表于 13-5-2013 02:07 PM
haha??未卜先知？？

什么？？ 我什么都不知道。。。

APULA

alanlam84 发表于 2-8-2012 10:51 PM
真的吗？？明天会起到什么价位？

再接再力，再创高峰